APP and Alzheimer disease: In the APP/PS1 (chimeric mouse/human APP with mutant human presenilin 1) AD transgenic mouse model, chronic administration of JWH-015 (0.5 mg/kg i.p., daily for 8 weeks) reduced Iba1 expression in the cortex and promoted a shift in microglial phenotype from M1 to M2 type [260].